{"transactions":[{"id":701063,"issuer":{"id":6149,"kind":"organization","name":"COMPUGEN LTD"},"owners":[{"id":27888,"kind":"person","name":"Hukkelhoven Mathias","position":1,"cik":"0001936319","reported_name":"Hukkelhoven Mathias","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Share Option (right to buy)","published_at":"2026-07-30T20:04:25.000Z","date":"2026-07-29","kind":"grant","planned":false,"acquired":true,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This option vests 25% on October 1, 2027, and the remainder vests in 12 equal quarterly installments thereafter, subject to the Reporting Person's continued service to the Issuer."}],"balance_after":10000,"derivative":{"exercise_price":2.26,"expiration_date":"2036-07-29","underlying":"Ordinary Shares","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0001178913-26-003713","document":"zk2635768.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1936319/000117891326003713/zk2635768.xml","form_type":"4"}},{"id":701062,"issuer":{"id":6149,"kind":"organization","name":"COMPUGEN LTD"},"owners":[{"id":27888,"kind":"person","name":"Hukkelhoven Mathias","position":1,"cik":"0001936319","reported_name":"Hukkelhoven Mathias","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Ordinary Shares","published_at":"2026-07-30T20:04:25.000Z","date":"2026-07-29","kind":"grant","planned":false,"acquired":true,"shares":7500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents a restricted stock unit (\"RSU\") award. The RSUs vest 25% on October 1, 2027, and the remainder vests in 12 equal quarterly installments thereafter, subject to the Reporting Person's continued service to the Issuer."}],"balance_after":17500,"source":{"system":"sec-edgar","filing":"0001178913-26-003713","document":"zk2635768.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1936319/000117891326003713/zk2635768.xml","form_type":"4"}},{"id":728205,"issuer":{"id":35581,"kind":"organization","name":"Centessa Pharmaceuticals plc","symbol":"CNTA"},"owners":[{"id":27888,"kind":"person","name":"Hukkelhoven Mathias","position":1,"cik":"0001936319","reported_name":"Hukkelhoven Mathias","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Share Option (right to buy)","published_at":"2026-06-24T20:15:45.000Z","date":"2026-06-24","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":40000,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On June 24, 2026, Eli Lilly and Company (\"Parent\"), through its wholly owned subsidiary LDH XV Corporation (\"Purchaser\"), acquired all outstanding Ordinary Shares of Centessa Pharmaceuticals plc (the \"Company\") by means of a scheme of arrangement under Part 26 of the UK Companies Act 2006 (the \"Scheme of Arrangement\"), pursuant to the Transaction Agreement dated as of March 31, 2026, by and among the Company, Parent and Purchaser (the \"Transaction Agreement\")."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Pursuant to the Transaction Agreement, at the effective time of the Scheme of Arrangement, each outstanding share option, whether or not vested, was automatically cancelled and converted into the right to receive (i) an amount in cash equal to the excess of $38.00 in cash over the per-share exercise price of such option, without interest and less any applicable withholding taxes, and (ii) one non-transferable contingent value right (a \"CVR\") per underlying Ordinary Share entitling the holders to receive contingent payments of up to an aggregate of $9.00 per Ordinary Share, without interest and less any applicable withholding taxes, contingent upon the achievement of specified milestones set forth in the Contingent Value Rights Agreement between Parent, Purchaser and a rights agent mutually agreeable to the Company and Parent, in each case in accordance with the Transaction Agreement. No share options were exercised prior to the Effective Time."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Pursuant to the Transaction Agreement, at the effective time of the Scheme of Arrangement, each outstanding share option, whether or not vested, was automatically cancelled and converted into the right to receive (i) an amount in cash equal to the excess of $38.00 in cash over the per-share exercise price of such option, without interest and less any applicable withholding taxes, and (ii) one non-transferable contingent value right (a \"CVR\") per underlying Ordinary Share entitling the holders to receive contingent payments of up to an aggregate of $9.00 per Ordinary Share, without interest and less any applicable withholding taxes, contingent upon the achievement of specified milestones set forth in the Contingent Value Rights Agreement between Parent, Purchaser and a rights agent mutually agreeable to the Company and Parent, in each case in accordance with the Transaction Agreement. No share options were exercised prior to the Effective Time."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F3","text":"The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share."}],"balance_after":0,"derivative":{"exercise_price":12.43,"expiration_date":"2035-06-20","underlying":"Ordinary Shares","underlying_shares":40000},"source":{"system":"sec-edgar","filing":"0001470831-26-000611","document":"wk-form4_1782332142.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1936319/000147083126000611/wk-form4_1782332142.xml","form_type":"4"}},{"id":728204,"issuer":{"id":35581,"kind":"organization","name":"Centessa Pharmaceuticals plc","symbol":"CNTA"},"owners":[{"id":27888,"kind":"person","name":"Hukkelhoven Mathias","position":1,"cik":"0001936319","reported_name":"Hukkelhoven Mathias","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Share Option (right to buy)","published_at":"2026-06-24T20:15:45.000Z","date":"2026-06-24","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":48000,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On June 24, 2026, Eli Lilly and Company (\"Parent\"), through its wholly owned subsidiary LDH XV Corporation (\"Purchaser\"), acquired all outstanding Ordinary Shares of Centessa Pharmaceuticals plc (the \"Company\") by means of a scheme of arrangement under Part 26 of the UK Companies Act 2006 (the \"Scheme of Arrangement\"), pursuant to the Transaction Agreement dated as of March 31, 2026, by and among the Company, Parent and Purchaser (the \"Transaction Agreement\")."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Pursuant to the Transaction Agreement, at the effective time of the Scheme of Arrangement, each outstanding share option, whether or not vested, was automatically cancelled and converted into the right to receive (i) an amount in cash equal to the excess of $38.00 in cash over the per-share exercise price of such option, without interest and less any applicable withholding taxes, and (ii) one non-transferable contingent value right (a \"CVR\") per underlying Ordinary Share entitling the holders to receive contingent payments of up to an aggregate of $9.00 per Ordinary Share, without interest and less any applicable withholding taxes, contingent upon the achievement of specified milestones set forth in the Contingent Value Rights Agreement between Parent, Purchaser and a rights agent mutually agreeable to the Company and Parent, in each case in accordance with the Transaction Agreement. No share options were exercised prior to the Effective Time."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Pursuant to the Transaction Agreement, at the effective time of the Scheme of Arrangement, each outstanding share option, whether or not vested, was automatically cancelled and converted into the right to receive (i) an amount in cash equal to the excess of $38.00 in cash over the per-share exercise price of such option, without interest and less any applicable withholding taxes, and (ii) one non-transferable contingent value right (a \"CVR\") per underlying Ordinary Share entitling the holders to receive contingent payments of up to an aggregate of $9.00 per Ordinary Share, without interest and less any applicable withholding taxes, contingent upon the achievement of specified milestones set forth in the Contingent Value Rights Agreement between Parent, Purchaser and a rights agent mutually agreeable to the Company and Parent, in each case in accordance with the Transaction Agreement. No share options were exercised prior to the Effective Time."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F3","text":"The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share."}],"balance_after":0,"derivative":{"exercise_price":8.89,"expiration_date":"2034-06-25","underlying":"Ordinary Shares","underlying_shares":48000},"source":{"system":"sec-edgar","filing":"0001470831-26-000611","document":"wk-form4_1782332142.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1936319/000147083126000611/wk-form4_1782332142.xml","form_type":"4"}},{"id":728203,"issuer":{"id":35581,"kind":"organization","name":"Centessa Pharmaceuticals plc","symbol":"CNTA"},"owners":[{"id":27888,"kind":"person","name":"Hukkelhoven Mathias","position":1,"cik":"0001936319","reported_name":"Hukkelhoven Mathias","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Share Option (right to buy)","published_at":"2026-06-24T20:15:45.000Z","date":"2026-06-24","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":48000,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On June 24, 2026, Eli Lilly and Company (\"Parent\"), through its wholly owned subsidiary LDH XV Corporation (\"Purchaser\"), acquired all outstanding Ordinary Shares of Centessa Pharmaceuticals plc (the \"Company\") by means of a scheme of arrangement under Part 26 of the UK Companies Act 2006 (the \"Scheme of Arrangement\"), pursuant to the Transaction Agreement dated as of March 31, 2026, by and among the Company, Parent and Purchaser (the \"Transaction Agreement\")."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Pursuant to the Transaction Agreement, at the effective time of the Scheme of Arrangement, each outstanding share option, whether or not vested, was automatically cancelled and converted into the right to receive (i) an amount in cash equal to the excess of $38.00 in cash over the per-share exercise price of such option, without interest and less any applicable withholding taxes, and (ii) one non-transferable contingent value right (a \"CVR\") per underlying Ordinary Share entitling the holders to receive contingent payments of up to an aggregate of $9.00 per Ordinary Share, without interest and less any applicable withholding taxes, contingent upon the achievement of specified milestones set forth in the Contingent Value Rights Agreement between Parent, Purchaser and a rights agent mutually agreeable to the Company and Parent, in each case in accordance with the Transaction Agreement. No share options were exercised prior to the Effective Time."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Pursuant to the Transaction Agreement, at the effective time of the Scheme of Arrangement, each outstanding share option, whether or not vested, was automatically cancelled and converted into the right to receive (i) an amount in cash equal to the excess of $38.00 in cash over the per-share exercise price of such option, without interest and less any applicable withholding taxes, and (ii) one non-transferable contingent value right (a \"CVR\") per underlying Ordinary Share entitling the holders to receive contingent payments of up to an aggregate of $9.00 per Ordinary Share, without interest and less any applicable withholding taxes, contingent upon the achievement of specified milestones set forth in the Contingent Value Rights Agreement between Parent, Purchaser and a rights agent mutually agreeable to the Company and Parent, in each case in accordance with the Transaction Agreement. No share options were exercised prior to the Effective Time."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F3","text":"The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share."}],"balance_after":0,"derivative":{"exercise_price":6.35,"expiration_date":"2033-06-22","underlying":"Ordinary Shares","underlying_shares":48000},"source":{"system":"sec-edgar","filing":"0001470831-26-000611","document":"wk-form4_1782332142.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1936319/000147083126000611/wk-form4_1782332142.xml","form_type":"4"}},{"id":728202,"issuer":{"id":35581,"kind":"organization","name":"Centessa Pharmaceuticals plc","symbol":"CNTA"},"owners":[{"id":27888,"kind":"person","name":"Hukkelhoven Mathias","position":1,"cik":"0001936319","reported_name":"Hukkelhoven Mathias","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Share Option (right to buy)","published_at":"2026-06-24T20:15:45.000Z","date":"2026-06-24","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":96000,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On June 24, 2026, Eli Lilly and Company (\"Parent\"), through its wholly owned subsidiary LDH XV Corporation (\"Purchaser\"), acquired all outstanding Ordinary Shares of Centessa Pharmaceuticals plc (the \"Company\") by means of a scheme of arrangement under Part 26 of the UK Companies Act 2006 (the \"Scheme of Arrangement\"), pursuant to the Transaction Agreement dated as of March 31, 2026, by and among the Company, Parent and Purchaser (the \"Transaction Agreement\")."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Pursuant to the Transaction Agreement, at the effective time of the Scheme of Arrangement, each outstanding share option, whether or not vested, was automatically cancelled and converted into the right to receive (i) an amount in cash equal to the excess of $38.00 in cash over the per-share exercise price of such option, without interest and less any applicable withholding taxes, and (ii) one non-transferable contingent value right (a \"CVR\") per underlying Ordinary Share entitling the holders to receive contingent payments of up to an aggregate of $9.00 per Ordinary Share, without interest and less any applicable withholding taxes, contingent upon the achievement of specified milestones set forth in the Contingent Value Rights Agreement between Parent, Purchaser and a rights agent mutually agreeable to the Company and Parent, in each case in accordance with the Transaction Agreement. No share options were exercised prior to the Effective Time."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Pursuant to the Transaction Agreement, at the effective time of the Scheme of Arrangement, each outstanding share option, whether or not vested, was automatically cancelled and converted into the right to receive (i) an amount in cash equal to the excess of $38.00 in cash over the per-share exercise price of such option, without interest and less any applicable withholding taxes, and (ii) one non-transferable contingent value right (a \"CVR\") per underlying Ordinary Share entitling the holders to receive contingent payments of up to an aggregate of $9.00 per Ordinary Share, without interest and less any applicable withholding taxes, contingent upon the achievement of specified milestones set forth in the Contingent Value Rights Agreement between Parent, Purchaser and a rights agent mutually agreeable to the Company and Parent, in each case in accordance with the Transaction Agreement. No share options were exercised prior to the Effective Time."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F3","text":"The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share."}],"balance_after":0,"derivative":{"exercise_price":5.17,"expiration_date":"2032-07-01","underlying":"Ordinary Shares","underlying_shares":96000},"source":{"system":"sec-edgar","filing":"0001470831-26-000611","document":"wk-form4_1782332142.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1936319/000147083126000611/wk-form4_1782332142.xml","form_type":"4"}},{"id":1103293,"issuer":{"id":35581,"kind":"organization","name":"Centessa Pharmaceuticals plc","symbol":"CNTA"},"owners":[{"id":27888,"kind":"person","name":"Hukkelhoven Mathias","position":1,"cik":"0001936319","reported_name":"Hukkelhoven Mathias","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Share Option (right to buy)","published_at":"2025-06-24T20:12:39.000Z","date":"2025-06-20","kind":"grant","planned":false,"acquired":true,"shares":40000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to such option will vest in full on the earlier of (i) the first anniversary of the grant date or (ii) the Issuer's next annual meeting of shareholders, subject to continued service as a director through the applicable vesting date."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F2","text":"The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share."}],"balance_after":40000,"derivative":{"exercise_price":12.43,"expiration_date":"2035-06-20","underlying":"Ordinary Shares","underlying_shares":40000},"source":{"system":"sec-edgar","filing":"0001847903-25-000107","document":"wk-form4_1750795951.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1936319/000184790325000107/wk-form4_1750795951.xml","form_type":"4"}},{"id":1468461,"issuer":{"id":35581,"kind":"organization","name":"Centessa Pharmaceuticals plc","symbol":"CNTA"},"owners":[{"id":27888,"kind":"person","name":"Hukkelhoven Mathias","position":1,"cik":"0001936319","reported_name":"Hukkelhoven Mathias","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Share Option (right to buy)","published_at":"2024-06-27T20:33:12.000Z","date":"2024-06-25","kind":"grant","planned":false,"acquired":true,"shares":48000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to such option will vest in full on the earlier of (i) the first anniversary of the grant date or (ii) the Issuer's next annual meeting of shareholders, subject to continued service as a director through the applicable vesting date."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F2","text":"The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share."}],"balance_after":48000,"derivative":{"exercise_price":8.89,"expiration_date":"2034-06-25","underlying":"Ordinary Shares","underlying_shares":48000},"source":{"system":"sec-edgar","filing":"0001847903-24-000105","document":"wk-form4_1719520385.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1936319/000184790324000105/wk-form4_1719520385.xml","form_type":"4"}},{"id":1845855,"issuer":{"id":35581,"kind":"organization","name":"Centessa Pharmaceuticals plc","symbol":"CNTA"},"owners":[{"id":27888,"kind":"person","name":"Hukkelhoven Mathias","position":1,"cik":"0001936319","reported_name":"Hukkelhoven Mathias","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Share Option (right to buy)","published_at":"2023-06-23T21:05:51.000Z","date":"2023-06-22","kind":"grant","planned":false,"acquired":true,"shares":48000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to such option will vest in full on the earlier of (i) the first anniversary of the grant date or (ii) the Issuer's next annual meeting of shareholders, subject to continued service as a director through the applicable vesting date."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F2","text":"The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share."}],"balance_after":48000,"derivative":{"exercise_price":6.35,"expiration_date":"2033-06-22","underlying":"Ordinary Shares","underlying_shares":48000},"source":{"system":"sec-edgar","filing":"0001847903-23-000128","document":"wf-form4_168755433988755.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1936319/000184790323000128/wf-form4_168755433988755.xml","form_type":"4"}},{"id":2213260,"issuer":{"id":35581,"kind":"organization","name":"Centessa Pharmaceuticals plc","symbol":"CNTA"},"owners":[{"id":27888,"kind":"person","name":"Hukkelhoven Mathias","position":1,"cik":"0001936319","reported_name":"Hukkelhoven Mathias","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Share Option (right to buy)","published_at":"2022-07-06T22:15:12.000Z","date":"2022-07-01","kind":"grant","acquired":true,"shares":96000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to such option will vest in 36 equal monthly installments over three years from the grant date, subject to continued service as a director through the applicable vesting date."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F2","text":"The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share."}],"balance_after":96000,"derivative":{"exercise_price":5.17,"expiration_date":"2032-07-01","underlying":"Ordinary Shares","underlying_shares":96000},"source":{"system":"sec-edgar","filing":"0000899243-22-025470","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1936319/000089924322025470/doc4.xml","form_type":"4"}}]}